EnteroBiotix has secured £19 million in a follow-on funding round led by Thairm Bio and the Scottish National Investment Bank, bringing their total raised to over £65 million. This capital will primarily fund a 300-patient Phase 2b clinical trial for their IBS therapy, EBX-102-02, with data expected in H2 2027. The funds will also support pipeline advancement, manufacturing scale-up, and R&D.
Amount: $19.0M
